Posted on September 28, 2018 by Kirsten Dorsey
Join us while exhibits are open on October 6 to have your blood drawn by Accu Reference Medical Lab, a preferred GlycoMark lab partner and proud sponsor of conference attendee testing. The GlycoMark test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).…
Read More
Posted on September 25, 2018 by Kirsten Dorsey
New York, NY. Sept. 25th, 2018 – GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test…
Read More
Posted on September 11, 2018 by Kirsten Dorsey
Visit GlycoMark’s booth the Cardiometabolic Risk Summit in San Antonio, TX on September 14-15, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both). To schedule a meeting with one of our experts,…
Read More
The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.